Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …

Structural principles underlying the composition and synergistic mechanisms of protective
monoclonal antibody cocktails are poorly defined. Here, we exploited antibody cooperativity …

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Therapeutic
neutralizing antibodies constitute a key short-to-medium term approach to tackle COVID-19 …

The emergence of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern threatens the efficacy of currently approved vaccines and authorized …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged
coronavirus that is responsible for the current pandemic of coronavirus disease 2019 …

INTRODUCTION A systematic characterization of the humoral response to severe acute
respiratory system coronavirus 2 (SARS-CoV-2) epitopes has yet to be performed. This …